Cargando…

[(111)In-DOTA]Somatostatin-14 analogs as potential pansomatostatin-like radiotracers - first results of a preclinical study

BACKGROUND: In this study, we report on the synthesis, radiolabeling, and biological evaluation of two new somatostatin-14 (SS14) analogs, modified with the universal chelator DOTA. We were interested to investigate if and to what extent such radiotracer prototypes may be useful for targeting sst(1-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tatsi, Aikaterini, Maina, Theodosia, Cescato, Renzo, Waser, Beatrice, Krenning, Eric P, de Jong, Marion, Cordopatis, Paul, Reubi, Jean Claude, Nock, Berthold A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer 2012
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3407795/ https://www.ncbi.nlm.nih.gov/pubmed/22682002 http://dx.doi.org/10.1186/2191-219X-2-25

Ejemplares similares

Comparing Gly(11)/dAla(11)-Replacement vs. the in-Situ Neprilysin-Inhibition Approach on the Tumor-targeting Efficacy of the (111)In-SB3/(111)In-SB4 Radiotracer Pair
por: Lymperis, Emmanouil, et al.
Publicado: (2019)

Impact of clinically tested NEP/ACE inhibitors on tumor uptake of [(111)In-DOTA]MG11—first estimates for clinical translation
por: Kaloudi, Aikaterini, et al.
Publicado: (2016)

Localization of (99m)Tc-GRP Analogs in GRPR-Expressing Tumors: Effects of Peptide Length and Neprilysin Inhibition on Biological Responses
por: Kaloudi, Aikaterini, et al.
Publicado: (2019)

Novel dimeric DOTA-coupled peptidic Y(1)-receptor antagonists for targeting of neuropeptide Y receptor-expressing cancers
por: Chatenet, David, et al.
Publicado: (2011)

One Step Closer to Clinical Translation: Enhanced Tumor Targeting of [(99m)Tc]Tc-DB4 and [(111)In]In-SG4 in Mice Treated with Entresto
por: Kanellopoulos, Panagiotis, et al.
Publicado: (2020)

Nonpeptidic Z360-Analogs Tagged with Trivalent Radiometals as Anti-CCK(2)R Cancer Theranostic Agents: A Preclinical Study
por: Nock, Berthold A., et al.
Publicado: (2022)

[(99m)Tc]Tc-DB1 Mimics with Different-Length PEG Spacers: Preclinical Comparison in GRPR-Positive Models
por: Kanellopoulos, Panagiotis, et al.
Publicado: (2020)

[(68)Ga]Ga-DATA(5m)-LM4, a PET Radiotracer in the Diagnosis of SST(2)R-Positive Tumors: Preclinical and First Clinical Results
por: Kanellopoulos, Panagiotis, et al.
Publicado: (2022)

Optimizing the Profile of [(99m)Tc]Tc–NT(7–13) Tracers in Pancreatic Cancer Models by Means of Protease Inhibitors
por: Kanellopoulos, Panagiotis, et al.
Publicado: (2020)

Toward Stability Enhancement of NTS(1)R-Targeted Radioligands: Structural Interventions on [(99m)Tc]Tc-DT1
por: Kanellopoulos, Panagiotis, et al.
Publicado: (2023)

Key-Protease Inhibition Regimens Promote Tumor Targeting of Neurotensin Radioligands
por: Kanellopoulos, Panagiotis, et al.
Publicado: (2020)

Improved radiotracing of oxytocin receptor-expressing tumours using the new [(111)In]-DOTA-Lys(8)-deamino-vasotocin analogue
por: Chini, B, et al.
Publicado: (2003)

Radiolabeled Bombesin Analogs
por: Mansi, Rosalba, et al.
Publicado: (2021)

Side-Chain Modified [(99m)Tc]Tc-DT1 Mimics: A Comparative Study in NTS(1)R-Positive Models
por: Kanellopoulos, Panagiotis, et al.
Publicado: (2023)

GPR87 Is an Overexpressed G-Protein Coupled Receptor in Squamous Cell Carcinoma of the Lung
por: Gugger, Mathias, et al.
Publicado: (2008)

DOTA-Derivatives of Octreotide Dicarba-Analogs with High Affinity for Somatostatin sst(2,5) Receptors
por: Pratesi, Alessandro, et al.
Publicado: (2017)

Imaging inflammation in atherosclerotic plaques, targeting SST(2) with [(111)In]In-DOTA-JR11
por: Meester, Eric J., et al.
Publicado: (2020)

Targeting prostate cancer with radiolabelled bombesins
por: Maina, Theodosia, et al.
Publicado: (2006)

AIP-mutated acromegaly resistant to first-generation somatostatin analogs: long-term control with pasireotide LAR in two patients
por: Daly, Adrian F, et al.
Publicado: (2019)

Distribution of somatostatin receptors in normal and neoplastic human tissues: recent advances and potential relevance.
por: Reubi, J. C., et al.
Publicado: (1997)

[(111)In]In/[(177)Lu]Lu-AAZTA(5)-LM4 SST(2)R-Antagonists in Cancer Theranostics: From Preclinical Testing to First Patient Results
por: Nock, Berthold A., et al.
Publicado: (2023)

Preclinical pharmacokinetics, biodistribution, radiation dosimetry and toxicity studies required for regulatory approval of a phase I clinical trial with (111)In-CP04 in medullary thyroid carcinoma patients
por: Maina, Theodosia, et al.
Publicado: (2016)

[(99m)Tc]Tc-DB15 in GRPR-Targeted Tumor Imaging with SPECT: From Preclinical Evaluation to the First Clinical Outcomes
por: Nock, Berthold A., et al.
Publicado: (2021)

Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [(177)Lu-DOTA(0),Tyr(3)]octreotate
por: de Keizer, Bart, et al.
Publicado: (2008)

Somatostatin receptors in the gastrointestinal tract in health and disease.
por: Reubi, J. C.
Publicado: (1992)

Preclinical Characterization of a Stabilized Gastrin-Releasing Peptide Receptor Antagonist for Targeted Cancer Theranostics
por: Abouzayed, Ayman, et al.
Publicado: (2023)

Localization of Small‐cell Lung Cancer Xenografts with Iodine‐125‐, Indium‐111‐, and Rhenium‐188‐Somatostatin Analogs
por: Hosono, Makoto, et al.
Publicado: (1996)

The Search for an Alternative to [(68)Ga]Ga-DOTA-TATE in Neuroendocrine Tumor Theranostics: Current State of (18)F-labeled Somatostatin Analog Development
por: Waldmann, Christopher M., et al.
Publicado: (2019)

Peptide Radioligands in Cancer Theranostics: Agonists and Antagonists
por: Nock, Berthold A., et al.
Publicado: (2023)

NeoBOMB1, a GRPR-Antagonist for Breast Cancer Theragnostics: First Results of a Preclinical Study with [(67)Ga]NeoBOMB1 in T-47D Cells and Tumor-Bearing Mice
por: Kaloudi, Aikaterini, et al.
Publicado: (2017)

Highly variable biodistribution of (68)Ga labeled somatostatin analogues (68)Ga-DOTA-NOC and (68)Ga-DOTA-TATE in neuroendocrine tumors: clinical implications for somatostatin receptor directed PET/CT
por: Cheng, Monica, et al.
Publicado: (2022)

Pre-clinical quantitative imaging and mouse-specific dosimetry for (111)In-labelled radiotracers
por: Denis-Bacelar, Ana M., et al.
Publicado: (2016)

SAT-575 Radiolabeled Somatostatin Receptor Analog (86)Y-EB-TATE is Characterized by Superior Tumor Uptake Compared to (68)Ga-DOTA-TATE and (68)Ga-DOTA-JR11 in Thyroid Cancer Mice Models
por: Thakur, Shilpa, et al.
Publicado: (2019)

Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [(177)Lu-DOTA(0),Tyr(3)]octreotate
por: Kwekkeboom, D. J., et al.
Publicado: (2003)

Effects of somatostatin analogs on uptake of radiolabeled somatostatin analogs on imaging: a systematic review and meta-analysis
por: Wang, Rang, et al.
Publicado: (2023)

Preoperative (68)Ga-DOTA-Somatostatin Analog-PET/CT Hybrid Imaging Increases Detection Rate of Intra-abdominal Small Intestinal Neuroendocrine Tumor Lesions
por: Norlén, Olov, et al.
Publicado: (2017)

Comparative biodistribution of 12 (111)In-labelled gastrin/CCK2 receptor-targeting peptides
por: Laverman, Peter, et al.
Publicado: (2011)

Characterization of (111)In-labeled Glucose-Dependent Insulinotropic Polypeptide as a Radiotracer for Neuroendocrine Tumors
por: Willekens, Stefanie M. A., et al.
Publicado: (2018)

Improved labelling of DTPA- and DOTA-conjugated peptides and antibodies with (111)In in HEPES and MES buffer
por: Brom, Maarten, et al.
Publicado: (2012)

Correlation of Somatostatin Receptor-2 Expression with Gallium-68-DOTA-TATE Uptake in Neuroblastoma Xenograft Models
por: Zhang, Libo, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_abh53l57s2rjrfi3e4kvcrh4s7